Sep. 3 at 6:20 PM
Leerink⬆️
$WVE's PT to
$26 from
$24, reit'd Outperform & said it thinks invs should take advantage of weakness to buy, ahead of add'l important catalysts, which they remain optimistic investors will appreciate.
$GSK $ARWR TAK
$KRRO SNY NTLA BEAM
$LLY NVO VKTX GPCR
Raymond James reit'd
$WVE Outperform-
$14 & said, We continue to view
$WVE's wholly-owned gene-editing programs as more likely LT value drivers - sees WVE-007 (INHBE) in obesity (4Q 2025) as the most important near-term stock-moving catalyst, with an attractive risk/ reward skew.
Leerink and Raymond James said in their notes to investors:
